Drug Profile
Research programme: malaria therapeutics - Shreya Life Sciences
Latest Information Update: 12 Sep 2023
Price :
$50
*
At a glance
- Originator Shreya Life Sciences
- Developer National Institute of Oceanography; Shreya Life Sciences
- Class Antimalarials
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Malaria
Most Recent Events
- 12 Sep 2023 Discontinued - Preclinical for Malaria in India (unspecified route) (Shreya Life Sciences website, September 2023)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Malaria in India
- 25 Jul 2016 Preclinical trials in Malaria in India (unspecified route)